Supply Chain Professionals Should Know What About Cell and Gene Therapies?

Cell and gene therapies (CGTs) are a rapidly growing field of medicine that offers the potential to cure a wide range of diseases, including cancer, rare diseases, and autoimmune disorders. However, the supply chain for CGTs is complex and challenging, requiring a deep understanding of the unique requirements of these therapies.

𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻: Cell and gene therapies are personalized, meaning that each patient's therapy is 𝗺𝗮𝗱𝗲 𝘁𝗼 𝗼𝗿𝗱𝗲𝗿. This requires a high degree of flexibility and agility in the supply chain.

𝗧𝗲𝗺𝗽𝗲𝗿𝗮𝘁𝘂𝗿𝗲 𝗦𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗶𝘁𝘆: Cell and gene therapies must be stored and transported at a cold temperature, typically -𝟴𝟬°𝗖 or below. This adds complexity to the supply chain and requires specialized equipment and trained personnel.

𝗦𝗵𝗼𝗿𝘁 𝗦𝗵𝗲𝗹𝗳 𝗟𝗶𝗳𝗲: Cell and gene therapies have a short shelf life, typically only a few days or weeks. This further complicates the supply chain and requires careful planning to ensure the therapies are delivered to patients on time.

𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: Cell and gene therapies are subject to strict regulatory requirements. This can add complexity to the supply chain and require careful documentation and tracking.

These challenges can make managing the supply chain for cell and gene therapies difficult. However, several solutions can be implemented to address these challenges.

𝗖𝗲𝗻𝘁𝗿𝗮𝗹𝗶𝘇𝗲𝗱 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴: This can help to improve efficiency and reduce costs.

𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗖𝗼𝗹𝗱 𝗖𝗵𝗮𝗶𝗻 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: This can help to ensure the safe and efficient transportation of cell and gene therapies.

𝗕𝗹𝗼𝗰𝗸𝗰𝗵𝗮𝗶𝗻 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: This can help to improve traceability and security.

𝗧𝗵𝗶𝗿𝗱-𝗣𝗮𝗿𝘁𝘆 𝗟𝗼𝗴𝗶𝘀𝘁𝗶𝗰𝘀 (𝟯𝗣𝗟) 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝗿𝘀: This can help to share expertise and resources.

The global market for these therapies is projected to skyrocket, growing from $6.02 billion in 2017 to $35.4 billion in 2026.

Companies like Marken, World Courier, QuickSTAT , Cryoport, and others are leading the charge, offering specialized services and technologies to meet the unique demands of cell and gene therapy logistics. Their efforts contribute to the successful commercialization of advanced therapies and ensure patients benefit from groundbreaking treatments.

Read also: Difference Between S&OP and S&OE

Resource Person: Omar Abu Louz

Post a Comment

Previous Post Next Post